Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 4, 2025

Chk1 (G-4)

RRID:AB_627257
Type: Antibody

Proper Citation

(Santa Cruz Biotechnology Cat# sc-8408, RRID:AB_627257)

Antibody Information

URL: http://antibodyregistry.org/AB_627257

Proper Citation: (Santa Cruz Biotechnology Cat# sc-8408, RRID:AB_627257)

Target Antigen: Chk1 (G-4)

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: Immunofluorescence; Flow Cytometry; Western Blot; ELISA; Immunoprecipitation; WB, IP, IF, FCM, ELISA

Antibody Name: Chk1 (G-4)

Description: This monoclonal targets Chk1 (G-4)

Target Organism: rat, mouse, human

Antibody ID: AB_627257

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-8408

Record Creation Time: 20231110T080358+0000

Record Last Update: 20241115T050514+0000

Ratings and Alerts

No rating or validation information has been found for Chk1 (G-4).

No alerts have been found for Chk1 (G-4).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 65 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Ubieto-Capella P, et al. (2024) A rewiring of DNA replication mediated by MRE11 exonuclease underlies primed-to-naive cell de-differentiation. Cell reports, 43(4), 114024.

Göder A, et al. (2024) DBF4, not DRF1, is the crucial regulator of CDC7 kinase at replication forks. The Journal of cell biology, 223(8).

Onji H, et al. (2024) Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. Oncogene, 43(32), 2475.

Arends T, et al. (2024) DUX4-induced HSATII transcription causes KDM2A/B-PRC1 nuclear foci and impairs DNA damage response. The Journal of cell biology, 223(5).

Muñoz S, et al. (2024) SIN3A histone deacetylase action counteracts MUS81 to promote stalled fork stability. Cell reports, 43(2), 113778.

van de Kooij B, et al. (2024) EXO1 protects BRCA1-deficient cells against toxic DNA lesions. Molecular cell, 84(4), 659.

Day CA, et al. (2024) The histone H3.3 K27M mutation suppresses Ser31phosphorylation and mitotic fidelity, which can directly drive gliomagenesis. Current biology : CB.

Egger T, et al. (2024) Spatial organization and functions of Chk1 activation by TopBP1 biomolecular condensates. Cell reports, 43(4), 114064.

Randolph ME, et al. (2024) RNA helicase DDX3 regulates RAD51 localization and DNA damage repair in Ewing sarcoma. iScience, 27(2), 108925.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience, 27(7), 109978.

Li S, et al. (2023) Cytosolic DNA sensing by cGAS/STING promotes TRPV2-mediated Ca2+ release to protect stressed replication forks. Molecular cell, 83(4), 556.

Lim Y, et al. (2023) In silico protein interaction screening uncovers DONSON's role in replication initiation. Science (New York, N.Y.), 381(6664), eadi3448.

Zhao Y, et al. (2023) Genome-scale mapping of DNA damage suppressors through phenotypic CRISPR-Cas9 screens. Molecular cell, 83(15), 2792.

Göder A, et al. (2023) PTBP1 enforces ATR-CHK1 signaling determining the potency of CDC7 inhibitors. iScience, 26(6), 106951.

Zhang J, et al. (2023) Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway. Cell, 186(11), 2361.

Egger T, et al. (2023) Detection of endogenous translesion DNA synthesis in single mammalian cells. Cell reports methods, 3(6), 100501.

Bergkamp ND, et al. (2023) A virally encoded GPCR drives glioblastoma through feed-forward activation of the SK1-S1P1 signaling axis. Science signaling, 16(798), eade6737.

Kanhai AA, et al. (2023) Short salsalate administration affects cell proliferation, metabolism, and inflammation in polycystic kidney disease. iScience, 26(11), 108278.

Huffman BM, et al. (2023) A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(24), 5047.

Mannarino L, et al. (2022) Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations. Cell death & disease, 13(7), 612.